- Home
- EDIT vs NMRA Comparison
EDIT vs NMRA Comparison
Compare EDIT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- NMRA
- Stock Information
- Founded
- EDIT 2013
- NMRA 2019
- Country
- EDIT United States
- NMRA United States
- Employees
- EDIT N/A
- NMRA N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- NMRA
- Sector
- EDIT Health Care
- NMRA
- Exchange
- EDIT Nasdaq
- NMRA Nasdaq
- Market Cap
- EDIT 263.7M
- NMRA 268.5M
- IPO Year
- EDIT 2016
- NMRA 2023
- Fundamental
- Price
- EDIT $2.57
- NMRA $1.73
- Analyst Decision
- EDIT Buy
- NMRA Buy
- Analyst Count
- EDIT 12
- NMRA 8
- Target Price
- EDIT $5.40
- NMRA $7.14
- AVG Volume (30 Days)
- EDIT 1.7M
- NMRA 599.2K
- Earning Date
- EDIT 08-12-2025
- NMRA 08-06-2025
- Dividend Yield
- EDIT N/A
- NMRA N/A
- EPS Growth
- EDIT N/A
- NMRA N/A
- EPS
- EDIT N/A
- NMRA N/A
- Revenue
- EDIT $38,901,000.00
- NMRA N/A
- Revenue This Year
- EDIT N/A
- NMRA N/A
- Revenue Next Year
- EDIT N/A
- NMRA N/A
- P/E Ratio
- EDIT N/A
- NMRA N/A
- Revenue Growth
- EDIT N/A
- NMRA N/A
- 52 Week Low
- EDIT $0.91
- NMRA $0.61
- 52 Week High
- EDIT $4.12
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- EDIT 46.57
- NMRA 56.57
- Support Level
- EDIT $2.66
- NMRA $1.56
- Resistance Level
- EDIT $2.78
- NMRA $1.82
- Average True Range (ATR)
- EDIT 0.22
- NMRA 0.10
- MACD
- EDIT -0.02
- NMRA 0.00
- Stochastic Oscillator
- EDIT 39.39
- NMRA 79.07
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.